APLT vs. IPA, VLON, DMAC, IMUX, CLNN, HOOK, BLPH, RZLT, SYRS, and FBIO
Should you be buying Applied Therapeutics stock or one of its competitors? The main competitors of Applied Therapeutics include ImmunoPrecise Antibodies (IPA), Vallon Pharmaceuticals (VLON), DiaMedica Therapeutics (DMAC), Immunic (IMUX), Clene (CLNN), Hookipa Pharma (HOOK), Bellerophon Therapeutics (BLPH), Rezolute (RZLT), Syros Pharmaceuticals (SYRS), and Fortress Biotech (FBIO). These companies are all part of the "pharmaceutical preparations" industry.
Applied Therapeutics vs.
Applied Therapeutics (NASDAQ:APLT) and ImmunoPrecise Antibodies (NASDAQ:IPA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.
Applied Therapeutics received 60 more outperform votes than ImmunoPrecise Antibodies when rated by MarketBeat users. However, 80.00% of users gave ImmunoPrecise Antibodies an outperform vote while only 53.78% of users gave Applied Therapeutics an outperform vote.
Applied Therapeutics currently has a consensus target price of $7.08, suggesting a potential upside of 385.16%. ImmunoPrecise Antibodies has a consensus target price of $8.00, suggesting a potential upside of 172.11%. Given Applied Therapeutics' higher possible upside, analysts clearly believe Applied Therapeutics is more favorable than ImmunoPrecise Antibodies.
ImmunoPrecise Antibodies has higher revenue and earnings than Applied Therapeutics. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.
62.9% of Applied Therapeutics shares are owned by institutional investors. Comparatively, 5.7% of ImmunoPrecise Antibodies shares are owned by institutional investors. 19.1% of Applied Therapeutics shares are owned by company insiders. Comparatively, 6.8% of ImmunoPrecise Antibodies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Applied Therapeutics has a beta of 1.9, indicating that its share price is 90% more volatile than the S&P 500. Comparatively, ImmunoPrecise Antibodies has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500.
Applied Therapeutics has a net margin of 0.00% compared to ImmunoPrecise Antibodies' net margin of -128.71%. ImmunoPrecise Antibodies' return on equity of -39.29% beat Applied Therapeutics' return on equity.
In the previous week, Applied Therapeutics' average media sentiment score of 0.00 equaled ImmunoPrecise Antibodies' average media sentiment score.
Summary
ImmunoPrecise Antibodies beats Applied Therapeutics on 8 of the 15 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding APLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Applied Therapeutics Competitors List
Related Companies and Tools
